🟢 Adaptive Biotechnologies is trading 4.2% up today after strong Q2 results and raised MRD revenue guidance

Adaptive Biotechnologies is trading at $23.51 (4.2% up) after reporting strong second-quarter results and raising its full-year MRD revenue guidance.

• Revenue grew 22% year-over-year, driven by a 33% expansion in the core MRD business, which now accounts for 92% of total sales.
• Management outlined a clear path toward EBITDA profitability, helping shares rebound despite reporting a wider GAAP loss.